Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
39.043,45 +426,35 (+1,10%) EUR/USD
1,0828 +0,0001 (+0,01%) Bitcoin EUR
64.059,79 -429,31 (-0,67%) CMC Crypto 200
1.510,46 -15,96 (-1,05%)
Salarius Pharmaceuticals Inc (FP1.SG)
| Chiusura precedente | 0,4300 |
| Aperto | 0,4240 |
| Denaro | 0,4240 x N/D |
| Domanda | 0,4600 x N/D |
| Min-Max giorno | 0,4220 - 0,4240 |
| Intervallo di 52 settimane | 0,4100 - 1,6900 |
| Volume | |
| Media Volume | 0 |
| Capitalizzazione | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 08 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new
- GlobeNewswire
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o
- GlobeNewswire
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
The trial will assess the safety and preliminary efficacy of Salarius’ novel targeted protein degrader SP-3164; Patient dosing expected to begin in 2H 2023 The trial will also assess the utility of a gene signature to identify patients that are potentially sensitized to SP-3164 treatment and may be more likely to respond HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degrada
